[Metastatic castration-resistant prostate cancer].

Abstract excerpt

Metastatic castration-resistant prostate cancer (mCRPC) is considered as the final stage of the disease with limited therapeutic options to date. In this article, we review recent histopathologic and molecular pathologic findings that may expand our understanding of the disease and may lay, or have already laid the groundwork for the development of novel and individualized therapies. These include the detection...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Prostatic Neoplasms, Castration-Resistant